WO2004082571A3 - Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86) - Google Patents

Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86) Download PDF

Info

Publication number
WO2004082571A3
WO2004082571A3 PCT/EP2004/002245 EP2004002245W WO2004082571A3 WO 2004082571 A3 WO2004082571 A3 WO 2004082571A3 EP 2004002245 W EP2004002245 W EP 2004002245W WO 2004082571 A3 WO2004082571 A3 WO 2004082571A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
gpr86
diseases
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2004/002245
Other languages
French (fr)
Other versions
WO2004082571A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2004082571A2 publication Critical patent/WO2004082571A2/en
Publication of WO2004082571A3 publication Critical patent/WO2004082571A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G01N33/5735—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes co-enzymes or co-factors, e.g. NAD, ATP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a human GPR86 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, cancer disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, cancer disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR86 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/002245 2003-03-18 2004-03-05 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86) WO2004082571A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03005500.8 2003-03-18
EP03005500 2003-03-18

Publications (2)

Publication Number Publication Date
WO2004082571A2 WO2004082571A2 (en) 2004-09-30
WO2004082571A3 true WO2004082571A3 (en) 2004-12-23

Family

ID=33016825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/002245 WO2004082571A2 (en) 2003-03-18 2004-03-05 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)

Country Status (1)

Country Link
WO (1) WO2004082571A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1604669A1 (en) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
CA2572547A1 (en) * 2004-07-01 2006-01-12 Paradigm Therapeutics Limited Use of the receptor gpr86
US8211634B2 (en) * 2006-02-14 2012-07-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0913471A2 (en) * 1997-10-23 1999-05-06 Smithkline Beecham Corporation Cdna clone HNEAA81 that encodes a human 7-transmembrane receptor
US5955303A (en) * 1997-03-06 1999-09-21 Incyte Pharmaceuticals, Inc. Human chemokine receptor-like protein
WO2000053742A2 (en) * 1999-03-09 2000-09-14 Curagen Corporation Polynucleotides and proteins encoded thereby
US6162899A (en) * 1997-10-23 2000-12-19 Smithkline Beecham Corporation Human HNEAA81 receptor
US20010021509A1 (en) * 1997-10-23 2001-09-13 Sathe Ganesh Madhusudan cDNA clone HNEAA81 that encodes a human 7-transmembrane receptor
WO2003014731A2 (en) * 2001-08-07 2003-02-20 Euroscreen S.A. The natural ligand for orphan g protein coupled receptor gpr86 and methods of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955303A (en) * 1997-03-06 1999-09-21 Incyte Pharmaceuticals, Inc. Human chemokine receptor-like protein
EP0913471A2 (en) * 1997-10-23 1999-05-06 Smithkline Beecham Corporation Cdna clone HNEAA81 that encodes a human 7-transmembrane receptor
US6162899A (en) * 1997-10-23 2000-12-19 Smithkline Beecham Corporation Human HNEAA81 receptor
US20010021509A1 (en) * 1997-10-23 2001-09-13 Sathe Ganesh Madhusudan cDNA clone HNEAA81 that encodes a human 7-transmembrane receptor
WO2000053742A2 (en) * 1999-03-09 2000-09-14 Curagen Corporation Polynucleotides and proteins encoded thereby
WO2003014731A2 (en) * 2001-08-07 2003-02-20 Euroscreen S.A. The natural ligand for orphan g protein coupled receptor gpr86 and methods of use

Also Published As

Publication number Publication date
WO2004082571A2 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2005106492A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
WO2005095973A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2005103702A3 (en) Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2004080373A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
WO2005095972A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor etb (etb)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2005106489A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 5 (ccr5)
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2005108998A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor beta-3 adreno (adrb3)
WO2004104577A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
WO2005040824A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
WO2004082572A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 87 (gpr87)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2005003762A3 (en) Diagnostics and therapeutics for diseases associated with sensory neuron-specific g protein-coupled receptor 2 (snsr2)
WO2005040822A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 25 (gpr25)
WO2005040790A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
WO2004080374A3 (en) Diagnostics and therapeutics for diseases associated with phosphodi-esterase 1c (pde1c)
WO2004097422A3 (en) Diagnostics and therapeutics for diseases associated with calcitonin receptor (calcr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase